NO20043926L - Mikroorganismer som baerere av nukleotidsekvenser kodede for celleantigener anvendt ved behandling av tumorer - Google Patents

Mikroorganismer som baerere av nukleotidsekvenser kodede for celleantigener anvendt ved behandling av tumorer

Info

Publication number
NO20043926L
NO20043926L NO20043926A NO20043926A NO20043926L NO 20043926 L NO20043926 L NO 20043926L NO 20043926 A NO20043926 A NO 20043926A NO 20043926 A NO20043926 A NO 20043926A NO 20043926 L NO20043926 L NO 20043926L
Authority
NO
Norway
Prior art keywords
tumors
microorganisms
carriers
treatment
nucleotide sequences
Prior art date
Application number
NO20043926A
Other languages
English (en)
Norwegian (no)
Inventor
Werner Goebel
Ivaylo Gentschev
Ulf R Rapp
Joachim Fensterle
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of NO20043926L publication Critical patent/NO20043926L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/001149—Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001162—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/42—Salmonella
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
NO20043926A 2002-02-28 2004-09-20 Mikroorganismer som baerere av nukleotidsekvenser kodede for celleantigener anvendt ved behandling av tumorer NO20043926L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10208653A DE10208653A1 (de) 2002-02-28 2002-02-28 Mikroorganismus als Träger von Nukleotidsequenzen kodierend für Zellantigene zur Behandlung von Tumoren
PCT/DE2003/000471 WO2003072789A2 (de) 2002-02-28 2003-02-13 Mikroorganismen als träger von nukleotidsequenzen kodierend für zellantigene zur behandlung von tumoren

Publications (1)

Publication Number Publication Date
NO20043926L true NO20043926L (no) 2004-09-20

Family

ID=27762489

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043926A NO20043926L (no) 2002-02-28 2004-09-20 Mikroorganismer som baerere av nukleotidsekvenser kodede for celleantigener anvendt ved behandling av tumorer

Country Status (19)

Country Link
US (1) US20060105423A1 (pt)
EP (1) EP1478756A2 (pt)
JP (1) JP2005518795A (pt)
KR (1) KR20040104464A (pt)
CN (1) CN1650014A (pt)
AU (1) AU2003206664A1 (pt)
BR (1) BRPI0308119A2 (pt)
CA (1) CA2513190A1 (pt)
DE (1) DE10208653A1 (pt)
HR (1) HRP20040785A2 (pt)
IL (1) IL163672A0 (pt)
MX (1) MXPA04008287A (pt)
NO (1) NO20043926L (pt)
NZ (1) NZ535312A (pt)
PL (1) PL372370A1 (pt)
RS (1) RS75604A (pt)
RU (1) RU2319741C2 (pt)
WO (1) WO2003072789A2 (pt)
ZA (1) ZA200407528B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8221739B2 (en) 2004-04-29 2012-07-17 Botanic Oil Innovations, Inc. Method of cancer treatment
DK2119450T3 (da) 2005-11-29 2013-05-06 Actogenix Nv Induktion af mucosal tolerance over for pankreatisk ø-beta-celle-autoantigener
KR100818144B1 (ko) * 2006-02-15 2008-03-31 고려대학교 산학협력단 인터페론감마를 발현하는 살모넬라 균주 및 이를 함유하는항암 치료용 조성물
WO2008027560A2 (en) * 2006-09-01 2008-03-06 Anza Therapeutics, Inc. Holin-enhanced vaccines and reagents, and methods of use thereof
EP1921149A1 (en) 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
BRPI0807857A2 (pt) 2007-01-25 2014-05-27 Actogenix Nv Tratamento de doença imune por meio de distribuição através da mucosa de antígenos.
KR101104077B1 (ko) 2008-10-14 2012-01-11 건국대학교 산학협력단 Ｅｇｒ－１의 발현을 증가시키는 활성을 갖는 신규한 엔터로박테리아속에 속하는 신규균주 및 그 균주를 포함하는 조성물의 항암제로서의 용도
KR101346620B1 (ko) * 2011-11-30 2014-01-06 전남대학교산학협력단 신규 박테리아 용해 단백질 및 그의 용도
RU2551238C9 (ru) * 2013-08-02 2016-04-10 Федеральное государственное бюджетное учреждение "Медико-генетический научный центр" Российской академии медицинских наук Способ индукции апоптоза клеток злокачественной опухоли колоректального рака и средство для его осуществления
WO2018106754A1 (en) 2016-12-07 2018-06-14 Md Biosciences, Inc. Methods of synergistic treatment of cancer
CN111936166B (zh) * 2018-02-09 2024-10-22 国家科学与技术研究理事会(Conicet) 用于药物递送的免疫调节和免疫刺激多肽
US20220193149A1 (en) * 2019-05-16 2022-06-23 City Of Hope Compositions and methods for targeting tumor-associated extracellular matrix components to improve drug delivery
KR20220121245A (ko) 2019-12-26 2022-08-31 살스퍼라, 엘엘씨 고형 종양 암의 치료 방법 및 제제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU1438241C (ru) * 1987-04-22 1996-03-20 Институт биоорганической химии им.М.М.Шемякина и Ю.А.Овчинникова РАН Рекомбинантная плазмидная днк ртnf 33, кодирующая полипептид со свойствами фактора некроза опухоли человека, и штамм бактерий escherichia coli - продуцент полипептида со свойствами фактора некроза опухоли человека
RU1438240C (ru) * 1987-04-22 1996-03-20 Институт биоорганической химии им.М.М.Шемякина и Ю.А.Овчинникова РАН РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК РТNF 22, СОДЕРЖАЩАЯ ПОЛУСИНТЕТИЧЕСКИЙ ГЕН ФАКТОРА НЕКРОЗА ОПУХОЛИ ЧЕЛОВЕКА - ПРОМЕЖУТОЧНАЯ ПЛАЗМИДА ДЛЯ КОНСТРУИРОВАНИЯ РЕКОМБИНАНТНОЙ ПЛАЗМИДНОЙ ДНК pTNF 31, КОДИРУЮЩАЯ ПОЛИПЕПТИД СО СВОЙСТВАМИ ФАКТОРА НЕКРОЗА ОПУХОЛИ ЧЕЛОВЕКА, И ШТАММ БАКТЕРИЙ ESCHERICHIA COLI - ПРОДУЦЕНТ ПОЛИПЕПТИДА СО СВОЙСТВАМИ ФАКТОРА НЕКРОЗА ОПУХОЛИ ЧЕЛОВЕКА
RU1445193C (ru) * 1987-04-22 1996-03-20 Институт биоорганической химии им.М.М.Шемякина и Ю.А.Овчинникова РАН РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pGA 23 - ПРОМЕЖУТОЧНЫЙ ПРОДУКТ ДЛЯ КОНСТРУИРОВАНИЯ РЕКОМБИНАНТНОЙ ПЛАЗМИДНОЙ ДНК pTNF 311Δ,-/,, РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pTNF 311Δ,-/,, КОДИРУЮЩАЯ ПОЛИПЕПТИД СО СВОЙСТВАМИ ФАКТОРА НЕКРОЗА ОПУХОЛИ ЧЕЛОВЕКА И ШТАММ БАКТЕРИЙ ESCHERICHIA COLI - ПРОДУЦЕНТ ПОЛИПЕПТИДА СО СВОЙСТВАМИ ФАКТОРА НЕКРОЗА ОПУХОЛИ ЧЕЛОВЕКА
US5156841A (en) * 1988-08-26 1992-10-20 United States Of America Anti-tumor vaccine
ZA941645B (en) * 1994-03-09 1995-01-13 South To South Co Operation In Antibodies specifically reactive against human prostate specific antigen.
US6051237A (en) * 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
EP1412502B1 (en) * 2000-11-22 2010-07-21 University of Maryland, Baltimore Use of clya hemolysin for excretion of fusion proteins

Also Published As

Publication number Publication date
WO2003072789A3 (de) 2004-02-12
PL372370A1 (en) 2005-07-25
BRPI0308119A2 (pt) 2016-06-28
EP1478756A2 (de) 2004-11-24
JP2005518795A (ja) 2005-06-30
RU2319741C2 (ru) 2008-03-20
HRP20040785A2 (en) 2004-12-31
US20060105423A1 (en) 2006-05-18
IL163672A0 (en) 2005-12-18
ZA200407528B (en) 2006-06-28
CA2513190A1 (en) 2003-09-04
NZ535312A (en) 2008-03-28
RU2004128929A (ru) 2005-04-10
CN1650014A (zh) 2005-08-03
WO2003072789A2 (de) 2003-09-04
DE10208653A1 (de) 2003-09-18
KR20040104464A (ko) 2004-12-10
AU2003206664A1 (en) 2003-09-09
RS75604A (sr) 2006-12-15
MXPA04008287A (es) 2006-04-27

Similar Documents

Publication Publication Date Title
WO2002036743A3 (en) Antisense modulation of calreticulin expression
WO2005049630A3 (en) Antisense modulation of kinesin-like 1 expression
WO2004044181A3 (en) Antisense modulation of apolipoprotein b expression
WO2003097662A8 (en) Antisense modulation of apolipoprotein b expression
WO2004011610A3 (en) Antisense modulation of polo-like kinase expression
WO2008143668A3 (en) Indoleamine-2, 3-dioxygenase-2
NO20053206D0 (no) Fremgangsmate for produsering av ketokarotenoider ved dyrking av genetisk modifiserte organismer.
PL372370A1 (en) Microorganisms as carriers of nucleotide sequences coding for cell antigens used for the treatment of tumors
FI20020817A7 (fi) Pintakäsittelyprosessi
WO2003008545A3 (en) Antisense modulation of glioma-associated oncogene-2 expression
AU2003250983A1 (en) The use of nucleotide sequences as carrier of information
AU2003280010A1 (en) Methods for treating attention deficit disorder
ITRM20040578A1 (it) Processo e impianto per il trattamento di pile esauste.
WO2004010956A3 (en) Antisense modulation of lar expression
WO2003052062A3 (en) Antisense modulation of cd36l1 expression
WO2003099224A3 (en) Antisense moodulation of kinesin-like 1 expression
ZA200509966B (en) The treatment of water containing dissolved gases
KR100474967B1 (ko) 신규한 바실러스속 미생물 및 이를 이용한 2,6-나프탈렌디카르복실산의 정제방법
WO2003027229A3 (en) Antisense modulation of rip2 expression
ITMI20021917A1 (it) Attivatore per la formazione di gel piastrinico, gel di plasma povero di piastrine o gel di plasma ricco di piastrine.
WO2004001061A3 (en) Antisense modulation of heme oxygenase 1 expression
WO2004043398A3 (en) Modulation of jumonji expression
AU2002951011A0 (en) Water treatment process
WO2004014299A3 (en) Antisense modulation of resistin expression
WO2004048524A3 (en) Modulation of stat2 expression